Connect with us


FDA Approves CBD Clinical Trials To Treat Opioid Addiction




The Federal Drug Administration (FDA) recently gave a go-ahead to a biotech pharma company that is advancing human clinical trials –Ananda Scientific to test cannabidiol (CBD) use in treating opioid addiction.

The FDA has approved clinical trials for Nantheia™ ATL5 which is an investigational new drug (IND) that contains cannabis-based compound CBD that will be used as an adjunctive treatment using proprietary delivery technology. This will be the fourth IND approval for the CBD-based drug Nantheia™ product line which is being investigated for several indications. The study will be conducted in UCLA’s Jane and Terry Semel Institute for Neuroscience and Human Behavior.

The company CEO Sohail R. Zaidi has said that “This clinical study at UCLA is an important component of our clinical development efforts focused on opioid addiction, where a non-addictive therapy is a significant unmet need.” He further expressed his excitement with the partnership between Ananda and UCLA for this project.

Edythe London, Ph.D., and Richard De La Garza II, Ph.D. who work at the UCLA School of Medicine are the principal investigators spearheading the research. Funding for this clinical trial is coming from the National Institute on Drug Abuse (NIDA).

CBD is one of the numerous phytocannabinoids that are present in cannabis Sativa L. Unlike the other popular phytocannabinoid THC, CBD is non-psychoactive and will not alter one’s mental status. In 2018, the FDA approved the first-ever CBD-based drug Epidiolex for the treatment of severe childhood seizures: Lennox Gastaut and Dravets syndromes.

Ananda Scientific is a biotech and pharma company that is leading the way in investigating potential applications for cannabinoid-based treatments. It employs patented delivery technologies to ensure greater bioavailability and efficacy of such treatments. The company is running several clinical trials in partnership with leading universities. This privately held company is based out of Colorado and Los Angeles.


close News!

We’d love to keep you updated with our latest cannabis news, industry interviews, and offers.

We don’t spam! Read our privacy policy for more info.

Lydia K. (Bsc. RN) is a cannabis writer, which, considering where you’re reading this, makes perfect sense. Currently, she is a regular writer for Mace Media. In the past, she has written for MyBud, RX Leaf & Dine Magazine (Canada), CBDShopy (UK) and Cannavalate & Pharmadiol (Australia). She is best known for writing epic news articles and medical pieces. Occasionally, she deviates from news and science and creates humorous articles. And boy doesn't she love that! She equally enjoys ice cream, as should all right-thinking people.

Posts/Pages Sidebar Form

Advertiser Disclosure: is committed to rigorous editorial standards to provide our readers with accurate reviews and ratings. We may receive compensation when you click on links to products we reviewed.

Educational & Medical Disclaimer: This information is for educational purposes only. We are not medical professionals, and no information on this website should be construed as medical advice. For more information please view our Educational & Medical Disclaimer.

Minimum Age: To use this website you must be the minimum age as allowed in your jurisdiction. USA visitors must be 21, visitors from Canada must be 18 or 19 years of age depending on the province. It is illegal for a person younger than this to use this website.